Chugai Pharmaceutical Co Ltd

Company Profile

• Business description

  Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).

• Contact

  2-1-1 Muromachi, Nihonbashi
  12th Floor, Nihonbashi Mitsui Tower
  Chuo-ku
  Tokyo103-8324
  JPN

  T: +81 332816611

  https://www.chugai-pharm.co.jp

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - General

  Fiscal Year End

  31 December 2026

  Employees

  7,872